scispace - formally typeset
C

Carlos A. Guzmán

Researcher at University of Genoa

Publications -  281
Citations -  10481

Carlos A. Guzmán is an academic researcher from University of Genoa. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 54, co-authored 260 publications receiving 9506 citations. Previous affiliations of Carlos A. Guzmán include Hannover Medical School & Bill & Melinda Gates Foundation.

Papers
More filters
Journal ArticleDOI

Opacity Factor Activity and Epithelial Cell Binding by the Serum Opacity Factor Protein of Streptococcus pyogenes Are Functionally Discrete

TL;DR: In this article, the authors demonstrate that while the N terminus of SOF does not directly mediate intracellular uptake by epithelial cells, this domain enhances epithelial cell uptake mediated by full-length SOF, in comparison to the FnBD alone.
Journal ArticleDOI

Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein

TL;DR: It is demonstrated that vaccination with the H12 fragment stimulates long-lasting protective immunity and the adjuvant properties exhibited by the fibronectin-binding domain of the SfbI protein strength the potential of this antigen for inclusion in multi-component vaccines against S. pyogenes.
Journal ArticleDOI

The Mucosal Adjuvant Cyclic di-AMP Exerts Immune Stimulatory Effects on Dendritic Cells and Macrophages

TL;DR: It is shown that c-di-AMP induces the cell surface up-regulation of T cell co-stimulatory molecules as well as the production of interferon-β in dendritic cells and macrophages following mucosal administration.
Journal ArticleDOI

An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica is attenuated and immunogenic in a mouse model of infection

TL;DR: An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica, harbouring mutations in aroA and trpE to investigate the use of such a strain as a live-attenuated vaccine, showed significantly reduced abilities to invade and survive within the mouse macrophage-like cell line J774A.
Journal ArticleDOI

The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization

TL;DR: It is demonstrated that bis-(3′,5′)-cyclic dimeric adenosine monophosphate (c-di-AMP) constitutes a promising adjuvant candidate stimulating both effective Th1/Th2 and cytotoxic immune responses when included in mucosal or parenteral vaccine formulations.